Novo Nordisk A/SNVONYSE
Loading
Cash Flow PerformanceNormalizing
Percentile Rank71
3Y CAGR+10.6%
5Y CAGR+6.3%
Studio
Year-over-Year Change

Free cash flow yield

3Y CAGR
+10.6%/yr
vs -8.9%/yr prior
5Y CAGR
+6.3%/yr
Recent acceleration
Acceleration
+19.4pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive growthNormalizing
PeriodValueYoY Change
20254.08%+62.8%
20242.51%+12.0%
20232.24%-25.9%
20223.02%+7.0%
20212.82%-6.0%
20203.00%-22.5%
20193.87%-11.5%
20184.37%+11.1%
20173.94%-36.6%
20166.21%-